LSTA

Lisata Therapeutics, Inc. (NASDAQ:LSTA) is a clinical-stage biopharmaceutical company headquartered in Basking Ridge, New Jersey. Originally incorporated in 1980 as NeoStem, Inc., the company underwent significant transformations, first rebranding to Caladrius Biosciences in 2015 and then to its current name in September 2022 following a merger with Cend Therapeutics. The company has evolved from a broader cellular therapy focus to concentrate primarily on developing innovative cancer treatments using its proprietary CendR Platform technology. Today, Lisata operates as a development-stage biotechnology company with no marketed products, focusing its resources on advancing its lead drug candidate <b>certepetide</b> through multiple clinical trials for various solid tumor cancers.